StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Free Report) in a research report sent to investors on Sunday. The firm issued a sell rating on the stock.
Separately, Dawson James assumed coverage on shares of Tonix Pharmaceuticals in a research note on Wednesday, February 28th. They set a buy rating and a $3.00 price objective for the company.
Read Our Latest Analysis on TNXP
Tonix Pharmaceuticals Stock Performance
Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last issued its quarterly earnings results on Monday, April 1st. The company reported ($0.86) earnings per share for the quarter. The business had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.95 million. Equities research analysts predict that Tonix Pharmaceuticals will post -3.18 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. Sabby Management LLC purchased a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,247,465 shares of the company’s stock, valued at approximately $680,000. Tonix Pharmaceuticals accounts for approximately 0.5% of Sabby Management LLC’s portfolio, making the stock its 6th biggest position. Sabby Management LLC owned approximately 7.02% of Tonix Pharmaceuticals at the end of the most recent reporting period. 82.26% of the stock is owned by hedge funds and other institutional investors.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
See Also
- Five stocks we like better than Tonix Pharmaceuticals
- Investing in large cap stocks: Diving into big caps
- Garmin Navigates to New Highs Driven By Wearables Trend
- What is a buyback in stocks? A comprehensive guide for investors
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- How is Compound Interest Calculated?
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.